Instead of profiting from sales at high prices, the corporation would become eligible for a share of all payments made by the fund over the next ten years. The size of the share would be calculated by assessing the contribution the drug has made to reducing death and disability.
Au lieu de tirer des bénéfices de tarifs élevés, les entreprises seraient éligibles aux subventions du Fonds durant 10 ans, dont la taille et la proportion seraient calculées selon la contribution du médicament à réduire la mortalité et le handicap.